Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.515 USD | +1.33% | -1.57% | -16.46% |
13/05 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
13/05 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.46% | 46Cr | |
+30.54% | 59TCr | |
-3.42% | 36TCr | |
+18.02% | 33TCr | |
+4.27% | 29TCr | |
+14.77% | 24TCr | |
+9.84% | 21TCr | |
-7.48% | 20TCr | |
+8.12% | 17TCr | |
-1.42% | 16TCr |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Theravance Biopharma : HC Wainwright Adjusts Theravance Biopharma's Price Target to $21 From $32, Maintains Buy Rating